An EAACI Task Force Report: Recognising the Potential of the Primary Care Physician in the Diagnosis and Management of Drug Hypersensitivity
Overview
Affiliations
Adverse drug reactions include drug hypersensitivity reactions (DHRs), which can be immunologically mediated (allergy) or non-immunologically mediated. The high number of DHRs that are unconfirmed and often self-reported is a frequent problem in daily clinical practice, with considerable impact on future prescription choices and patient health. It is important to distinguish between hypersensitivity and non-hypersensitivity reactions by adopting a structured diagnostic approach to confirm or discard the suspected drug, not only to avoid life-threatening reactions, but also to reduce the frequent over-diagnosis of DHRs. Primary care physicians are often the first point of contact for the sufferer of a reaction, as such they have a key role in deciding whether to discard the diagnosis or send the patient for further investigation. In this review, we highlight the importance of diagnosing DHRs, analysing in detail the role of primary care physicians. We describe the common patterns of DHRs and signs of its progression, as well as the indications and contraindications for referring the patient to an allergist. The diagnostic process is described and the possible tests are discussed, which often depend on the drug involved and the type of DHR suspected. We also describe recommendations regarding the avoidance of medication suspected to have caused the reaction and the use of alternatives.
Editorial: Drug allergy in children.
Felix M, Boechat J, Kuschnir F, Castells M Front Allergy. 2024; 5:1530907.
PMID: 39737060 PMC: 11684478. DOI: 10.3389/falgy.2024.1530907.
Is the Anamnesis Enough to De-Label Patients with Reported Beta-Lactam Allergy?.
Rozlucka L, Rymarczyk B, Gawlik R, Gluck J J Clin Med. 2024; 13(23).
PMID: 39685725 PMC: 11642921. DOI: 10.3390/jcm13237267.
Recent findings on drug hypersensitivity in children.
Felix M, Kuschnir F, Boechat J, Castells M Front Allergy. 2024; 5:1330517.
PMID: 38384771 PMC: 10879301. DOI: 10.3389/falgy.2024.1330517.
Palapinyo S, Klaewsongkram J, Mongkolpathumrat P, Leelakanok N, Yotsombut K J Pharm Policy Pract. 2023; 16(1):12.
PMID: 36670475 PMC: 9863187. DOI: 10.1186/s40545-023-00513-8.
Clinical review: The suggested management pathway for urticaria in primary care.
Ryan D, Tanno L, Angier E, Clark E, Price D, Zuberbier T Clin Transl Allergy. 2022; 12(10):e12195.
PMID: 36225262 PMC: 9533216. DOI: 10.1002/clt2.12195.